Malignant Mesothelioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Malignant Mesothelioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Drugs In Development, 2022, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 56, 61, 1, 3, 48, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 7, 4, 2 and 8 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Malignant Mesothelioma – Overview
Malignant Mesothelioma – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Malignant Mesothelioma – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Malignant Mesothelioma – Companies Involved in Therapeutics Development
A2 Biotherapeutics Inc
AbbVie Inc
ADC Therapeutics SA
ADCendo ApS
Adienne Pharma & Biotech SA
Advenchen Laboratories LLC
AGC Biologics SpA
Akeso Inc
Aldeyra Therapeutics Inc
Alligator Bioscience AB
Almac Discovery Ltd
Amgen Inc
Amphera BV
AnGes Inc
Apollomics Inc
Applied Research using OMIC Sciences SL
Arch Oncology Inc
Ares Immunotherapy Inc
Argenx SE
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Avenge Bio Inc
Bao Kang Biomedical Healthcare Inc
Bayer AG
Beijing Immunochina Pharmaceuticals Co Ltd
BerGenBio ASA
BioAtla Inc
Biocad
Biosion Inc
Biotheus Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calithera Biosciences Inc
CanBas Co Ltd
Cancure Ltd
Canget BioTekpharma LLC
Cedilla Therapeutics
Cellectis SA
Checkpoint Therapeutics Inc
Chiome Bioscience Inc
Clovis Oncology Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Delta-Fly Pharma Inc
Dyadic International Inc
Eisai Co Ltd
Eli Lilly and Co
Enlivex Therapeutics Ltd
Epigene Therapeutics Inc
EpimAb Biotherapeutics Inc
Epizyme Inc
Eureka Therapeutics Inc
F. Hoffmann-La Roche Ltd
FatiAbGen Corp
Fidia farmaceutici SpA
FKD Therapies Oy
Flag Therapeutics Inc
Genelux Corp
GlaxoSmithKline Plc
H2Biologics Inc
Harpoon Therapeutics Inc
Hebei Senlang Biotechnology Co Ltd
HiFiBiO Therapeutics Inc
Horizon Therapeutics Plc
Hutchison MediPharma Ltd
IDAC Theranostics Inc
Ikena Oncology Inc
ImmuNext Inc
ImmunityBio Inc
Immuno Cure BioTech Ltd
Immvira Co Ltd
Incyte Corp
Infinity Pharmaceuticals Inc
Inhibrx Inc
Innovent Biologics Inc
Inventiva SA
Invion Ltd
iOnctura SA
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
Kezar Life Sciences Inc
Kirilys Therapeutics Inc
Kiromic BioPharma Inc
Kyowa Kirin Co Ltd
L.E.A.F. Pharmaceuticals LLC
Laboratoires Pierre Fabre SA
Les Laboratoires Servier SAS
Lipac Oncology LLC
LipoSeuticals Inc
Luye Pharma Group Ltd
Marino Biotechnology Co Ltd
MELEMA Pharma GmbH
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Mina Therapeutics Ltd
Minneamrita Therapeutics LLC
Mirati Therapeutics Inc
Molecular Partners AG
Momotaro-Gene Inc
MorphoSys AG
Nanjing Bioheng Biotech Co Ltd
Nanjing CART Medical Technology Co Ltd
Navrogen Inc
NeoTX Therapeutics Ltd
NGM Biopharmaceuticals Inc
Novartis AG
Nurix Therapeutics Inc
Oasmia Pharmaceutical AB
Oncotelic Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
OSE Immunotherapeutics SA
Papyrus Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Pharmaxis Ltd
PlumeStars Srl
Polaris Pharmaceuticals Inc
Purmx Therapeutics Co Ltd
Quadriga BioSciences Inc
Rain Therapeutics Inc
RemeGen Co Ltd
RS Oncology LLC
Samjin Pharm Co Ltd
Sanofi
Seagen Inc
SELLAS Life Sciences Group Inc
Shanghai GeneChem Co Ltd
Shionogi & Co Ltd
SOTIO Biotech AS
SpringWorks Therapeutics Inc
Symphogen A/S
SynOx Therapeutics Ltd
Takeda Pharmaceutical Co Ltd
Tango Therapeutics Inc
Targovax ASA
TCR2 Therapeutics Inc
Tmunity Therapeutics Inc
TRACON Pharmaceuticals Inc
TREAT U SA
Ultimovacs AS
VasGene Therapeutics Inc
Venus Remedies Ltd
Verastem Inc
Verismo Therapeutics
ViroStatics SRL
Vivace Therapeutics Inc
VM Discovery Inc
Waterstone Hanxbio Pty Ltd
Xencor Inc
Y's Therapeutics Co Ltd
Malignant Mesothelioma – Drug Profiles
(epirubicin + staurosporine) – Drug Profile
Product Description
Mechanism Of Action
A-2B694 – Drug Profile
Product Description
Mechanism Of Action
ABBV-368 – Drug Profile
Product Description
Mechanism Of Action
History of Events
abemaciclib – Drug Profile
Product Description
Mechanism Of Action
History of Events
ADC-5311 – Drug Profile
Product Description
Mechanism Of Action
AG-270 – Drug Profile
Product Description
Mechanism Of Action
History of Events
ALG.APV-527 – Drug Profile
Product Description
Mechanism Of Action
History of Events
alisertib – Drug Profile
Product Description
Mechanism Of Action
History of Events
ALM-201 – Drug Profile
Product Description
Mechanism Of Action
History of Events
AMG-994 – Drug Profile
Product Description
Mechanism Of Action
History of Events
amivantamab – Drug Profile
Product Description
Mechanism Of Action
History of Events
anetumab corixetan – Drug Profile
Product Description
Mechanism Of Action
History of Events
anetumab ravtansine – Drug Profile
Product Description
Mechanism Of Action
History of Events
anlotinib hydrochloride – Drug Profile
Product Description
Mechanism Of Action
History of Events
antibody-drug conjugates (ADCs) – Drug Profile
Product Description
Mechanism Of Action
History of Events
AO-176 – Drug Profile
Product Description
Mechanism Of Action
History of Events
APG-2449 – Drug Profile
Product Description
Mechanism Of Action
History of Events
ApoCell – Drug Profile
Product Description
Mechanism Of Action
History of Events
ASTX-295 – Drug Profile
Product Description
Mechanism Of Action
History of Events
ATA-3271 – Drug Profile
Product Description
Mechanism Of Action
History of Events
atezolizumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
AVB-001 – Drug Profile
Product Description
Mechanism Of Action
avelumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
aviscumine – Drug Profile
Product Description
Mechanism Of Action
History of Events
bemcentinib – Drug Profile
Product Description
Mechanism Of Action
History of Events
bevacizumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
BI-765179 – Drug Profile
Product Description
Mechanism Of Action
History of Events
brentuximab vedotin – Drug Profile
Product Description
Mechanism Of Action
History of Events
BSI-038 – Drug Profile
Product Description
Mechanism Of Action
CA-170 – Drug Profile
Product Description
Mechanism Of Action
History of Events
cadonilimab – Drug Profile
Product Description
Mechanism Of Action
History of Events
camrelizumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
CBA-1535 – Drug Profile
Product Description
Mechanism Of Action
History of Events
CBP-501 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Cellular Immunotherapy for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Cellular Immunotherapy for Solid Tumors – Drug Profile
Product Description
Mechanism Of Action
cisplatin – Drug Profile
Product Description
Mechanism Of Action
History of Events
CNC-332 – Drug Profile
Product Description
Mechanism Of Action
cosibelimab – Drug Profile
Product Description
Mechanism Of Action
History of Events
CPI-0209 – Drug Profile
Product Description
Mechanism Of Action
History of Events
CTB-101 – Drug Profile
Product Description
Mechanism Of Action
cusatuzumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
CX-2029 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Debio-0228 – Drug Profile
Product Description
Mechanism Of Action
History of Events
defactinib hydrochloride – Drug Profile
Product Description
Mechanism Of Action
History of Events
DFP-10825 – Drug Profile
Product Description
Mechanism Of Action
dostarlimab – Drug Profile
Product Description
Mechanism Of Action
History of Events
doxorubicin hydrochloride – Drug Profile
Product Description
Mechanism Of Action
History of Events
durvalumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
durvalumab + tremelimumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
ecubectedin – Drug Profile
Product Description
Mechanism Of Action
eganelisib – Drug Profile
Product Description
Mechanism Of Action
History of Events
elimusertib – Drug Profile
Product Description
Mechanism Of Action
emactuzumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
EMB-02 – Drug Profile
Product Description
Mechanism Of Action
FabG-12139 – Drug Profile
Product Description
Mechanism Of Action
History of Events
feladilimab – Drug Profile
Product Description
Mechanism Of Action
History of Events
FL-118 – Drug Profile
Product Description
Mechanism Of Action
History of Events
FLAG-094 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Fusion Protein to Target Mesothelin for Malignant Mesothelioma – Drug Profile
Product Description
Mechanism Of Action
Fusion Protein to Target Mesothelin for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
galinpepimut-S – Drug Profile
Product Description
Mechanism Of Action
History of Events
ganetespib – Drug Profile
Product Description
Mechanism Of Action
History of Events
gavocabtagene autoleucel – Drug Profile
Product Description
Mechanism Of Action
History of Events
GEN-0101 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy 2 to Target Mesothelin for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene therapy for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma – Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate SOCS3 for Malignant Pleural Mesothelioma – Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target FAP for Malignant Pleural Mesothelioma – Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target Mesothelin and CLDN18 for Oncology – Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target Mesothelin for Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma and Solid Tumor – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target Mesothelin for Malignant Plurel Mesothelioma and Metastatic Pancreatic Cancer – Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target Mesothelin for Oncology – Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target Mesothelin for Solid Tumor – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target Mesothelin for Solid Tumors – Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target MSLN for Solid Tumors – Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Target WT1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene-Modified Cell Therapy to Target 5T4 for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
geptanolimab – Drug Profile
Product Description
Mechanism Of Action
History of Events
GrB-Fc-SD1 – Drug Profile
Product Description
Mechanism Of Action
History of Events
HFB-200301 – Drug Profile
Product Description
Mechanism Of Action
History of Events
HMPL-453 – Drug Profile
Product Description
Mechanism Of Action
History of Events
HPN-536 – Drug Profile
Product Description
Mechanism Of Action
History of Events
HX-009 – Drug Profile
Product Description
Mechanism Of Action
History of Events
HXR-9 – Drug Profile
Product Description
Mechanism Of Action
IAG-933 – Drug Profile
Product Description
Mechanism Of Action
History of Events
IBI-323 – Drug Profile
Product Description
Mechanism Of Action
History of Events
iCasp9M28z – Drug Profile
Product Description
Mechanism Of Action
History of Events
ieramilimab – Drug Profile
Product Description
Mechanism Of Action
History of Events
IK-930 – Drug Profile
Product Description
Mechanism Of Action
History of Events
IM-81 – Drug Profile
Product Description
Mechanism Of Action
IMC-003 – Drug Profile
Product Description
Mechanism Of Action
INBRX-109 – Drug Profile
Product Description
Mechanism Of Action
History of Events
INCAGN-2385 – Drug Profile
Product Description
Mechanism Of Action
History of Events
interferon gamma-1b – Drug Profile
Product Description
Mechanism Of Action
History of Events
IOA-244 – Drug Profile
Product Description
Mechanism Of Action
History of Events
ipilimumab + nivolumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
ipilimumab biosimilar – Drug Profile
Product Description
Mechanism Of Action
History of Events
IVX-MES – Drug Profile
Product Description
Mechanism Of Action
JTCR-016 – Drug Profile
Product Description
Mechanism Of Action
History of Events
K-975 – Drug Profile
Product Description
Mechanism Of Action
KB-9520 – Drug Profile
Product Description
Mechanism Of Action
History of Events
KPT-276 – Drug Profile
Product Description
Mechanism Of Action
History of Events
KRLS-017 – Drug Profile
Product Description
Mechanism Of Action
History of Events
KZR-261 – Drug Profile
Product Description
Mechanism Of Action
History of Events
LEAF-1401 – Drug Profile
Product Description
Mechanism Of Action
LEAF-1701 – Drug Profile
Product Description
Mechanism Of Action
LEAF-1702 – Drug Profile
Product Description
Mechanism Of Action
LEAF-1703 – Drug Profile
Product Description
Mechanism Of Action
lenvatinib mesylate – Drug Profile
Product Description
Mechanism Of Action
History of Events
LMB-100 – Drug Profile
Product Description
Mechanism Of Action
History of Events
lurbinectedin – Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3434172 – Drug Profile
Product Description
Mechanism Of Action
History of Events
mecbotamab vedotin – Drug Profile
Product Description
Mechanism Of Action
History of Events
MesoCancerVac – Drug Profile
Product Description
Mechanism Of Action
History of Events
methoxyamine hydrochloride – Drug Profile
Product Description
Mechanism Of Action
History of Events
milademetan – Drug Profile
Product Description
Mechanism Of Action
History of Events
Minnelide – Drug Profile
Product Description
Mechanism Of Action
History of Events
mipasetamab uzoptirine – Drug Profile
Product Description
Mechanism Of Action
History of Events
MIRX-002 – Drug Profile
Product Description
Mechanism Of Action
MK-4830 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
MP-0310 – Drug Profile
Product Description
Mechanism Of Action
History of Events
MP-0317 – Drug Profile
Product Description
Mechanism Of Action
History of Events
MRTX-9768 – Drug Profile
Product Description
Mechanism Of Action
History of Events
MT-954 – Drug Profile
Product Description
Mechanism Of Action
MTG-201 – Drug Profile
Product Description
Mechanism Of Action
History of Events
MTL-CEBPA – Drug Profile
Product Description
Mechanism Of Action
History of Events
nadofaragene firadenovec – Drug Profile
Product Description
Mechanism Of Action
History of Events
naptumomab estafenatox – Drug Profile
Product Description
Mechanism Of Action
History of Events
NAV-001 – Drug Profile
Product Description
Mechanism Of Action
NAX-035 – Drug Profile
Product Description
Mechanism Of Action
NEO-2734 – Drug Profile
Product Description
Mechanism Of Action
History of Events
NGM-438 – Drug Profile
Product Description
Mechanism Of Action
NGM-707 – Drug Profile
Product Description
Mechanism Of Action
History of Events
NGR-hTNF – Drug Profile
Product Description
Mechanism Of Action
History of Events
niraparib – Drug Profile
Product Description
Mechanism Of Action
History of Events
NIU-440 – Drug Profile
Product Description
Mechanism Of Action
History of Events
nivolumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
nivolumab biosimilar – Drug Profile
Product Description
Mechanism Of Action
nofazinlimab – Drug Profile
Product Description
Mechanism Of Action
History of Events
numidargistat – Drug Profile
Product Description
Mechanism Of Action
History of Events
NX-1607 – Drug Profile
Product Description
Mechanism Of Action
History of Events
olaparib – Drug Profile
Product Description
Mechanism Of Action
History of Events
olvimulogene nanivacirepvec – Drug Profile
Product Description
Mechanism Of Action
History of Events
Oncofid-P-B – Drug Profile
Product Description
Mechanism Of Action
History of Events
ONCOS-102 – Drug Profile
Product Description
Mechanism Of Action
History of Events
onvatilimab – Drug Profile
Product Description
Mechanism Of Action
History of Events
OSE-703 – Drug Profile
Product Description
Mechanism Of Action
History of Events
paclitaxel – Drug Profile
Product Description
Mechanism Of Action
History of Events
pegargiminase – Drug Profile
Product Description
Mechanism Of Action
History of Events
pembrolizumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
pemetrexed disodium – Drug Profile
Product Description
Mechanism Of Action
penpulimab – Drug Profile
Product Description
Mechanism Of Action
Peptides to Inhibit YAP for Mesothelioma – Drug Profile
Product Description
Mechanism Of Action
PM-3006 – Drug Profile
Product Description
Mechanism Of Action
Poly-ICLC – Drug Profile
Product Description
Mechanism Of Action
History of Events
prolgolimab – Drug Profile
Product Description
Mechanism Of Action
History of Events
PXS-5505A – Drug Profile
Product Description
Mechanism Of Action
PYTX-001 – Drug Profile
Product Description
Mechanism Of Action
QBS-10072S – Drug Profile
Product Description
Mechanism Of Action
History of Events
ramucirumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
RC-88 – Drug Profile
Product Description
Mechanism Of Action
History of Events
rucaparib camsylate – Drug Profile
Product Description
Mechanism Of Action
History of Events
S-588210 – Drug Profile
Product Description
Mechanism Of Action
History of Events
SAR-444245 – Drug Profile
Product Description
Mechanism Of Action
History of Events
selicrelumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
SG-001 – Drug Profile
Product Description
Mechanism Of Action
History of Events
SGNCD-228A – Drug Profile
Product Description
Mechanism Of Action
History of Events
SJP-1901 – Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Malignant Mesothelioma and Squamous Cell Carcinoma – Drug Profile
Product Description
Mechanism Of Action
SOT-101 – Drug Profile
Product Description
Mechanism Of Action
History of Events
spartalizumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
Stenoparib – Drug Profile
Product Description
Mechanism Of Action
History of Events
Sym-024 – Drug Profile
Product Description
Mechanism Of Action
History of Events
T-3011 – Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-500 – Drug Profile
Product Description
Mechanism Of Action
History of Events
talazoparib – Drug Profile
Product Description
Mechanism Of Action
History of Events
tazemetostat hydrobromide – Drug Profile
Product Description
Mechanism Of Action
History of Events
TEAD Inhibitor Program – Drug Profile
Product Description
Mechanism Of Action
History of Events
telaglenastat hydrochloride – Drug Profile
Product Description
Mechanism Of Action
History of Events
teserpaturev – Drug Profile
Product Description
Mechanism Of Action
thiostrepton – Drug Profile
Product Description
Mechanism Of Action
TNG-908 – Drug Profile
Product Description
Mechanism Of Action
History of Events
trabectedin – Drug Profile
Product Description
Mechanism Of Action
History of Events
trabedersen – Drug Profile
Product Description
Mechanism Of Action
History of Events
UCARTMESO – Drug Profile
Product Description
Mechanism Of Action
UV-1 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Oncology – Drug Profile
Product Description
Mechanism Of Action
Vaccine to Target WT1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
Vargatef – Drug Profile
Product Description
Mechanism Of Action
History of Events
Vas-01 – Drug Profile
Product Description
Mechanism Of Action
History of Events
VIC-008 – Drug Profile
Product Description
Mechanism Of Action
vinorelbine tartrate – Drug Profile
Product Description
Mechanism Of Action
History of Events
VMD-928 – Drug Profile
Product Description
Mechanism Of Action
History of Events
VRT-002P – Drug Profile
Product Description
Mechanism Of Action
VS-2370 – Drug Profile
Product Description
Mechanism Of Action
History of Events
VT-3989 – Drug Profile
Product Description
Mechanism Of Action
History of Events
vudalimab – Drug Profile
Product Description
Mechanism Of Action
Yap-Tead – Drug Profile
Product Description
Mechanism Of Action
History of Events
YS-110 – Drug Profile
Product Description
Mechanism Of Action
History of Events
YTR-1 – Drug Profile
Product Description
Mechanism Of Action
zeluvalimab – Drug Profile
Product Description
Mechanism Of Action
History of Events
Malignant Mesothelioma – Dormant Projects
Malignant Mesothelioma – Discontinued Products
Malignant Mesothelioma – Product Development Milestones
Featured News & Press Releases
Apr 27, 2022: Ascentage Pharma to present data on APG-2449 at the 2022 American Society of Clinical Oncology Annual Meeting
Apr 13, 2022: Ascentage Pharma presents latest results from preclinical study of APG-2449 at AACR Annual Meeting 2022 9
Mar 08, 2022: Ascentage Pharma to present latest results from APG-2449 preclinical studies at AACR Annual Meeting 2022
Feb 09, 2022: With 3 years minimum follow-up, nivolumab plus ipilimumab continues to provide long-term survival benefit over chemotherapy in unresectable malignant pleural mesothelioma
Jan 26, 2022: SELLAS Life Sciences announces IND acceptance for first clinical trial of GPS in China
Jan 19, 2022: Oncotelic presenting at BiotechGate Digital Partnering
Jan 17, 2022: Targovax granted patents for ONCOS-102 in combination with chemotherapy in China and Japan
Dec 20, 2021: Targovax: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma
Dec 01, 2021: Oncotelic initiates phase 2 trial evaluating OT-101 in combination with KEYTRUDA for mesothelioma
Nov 12, 2021: MiNA Therapeutics highlights clinical data supporting the further development of mtl-cebpa as an anti-cancer immunotherapy
Nov 09, 2021: Targovax announces two posters at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 02, 2021: Ikena Oncology announces FDA acceptance of IND application of novel TEAD inhibitor IK-930
Oct 20, 2021: Oncotelic announces update on the OT-101 clinical programs including C001 COVID study
Oct 06, 2021: Targovax ASA: Two abstracts accepted at the SITC Congress
Sep 24, 2021: Targovax granted European patent for ONCOS-102 in combination with chemotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Malignant Mesothelioma, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
Table 9: Number of Products under Development by Companies, 2022 (Contd..7)
Table 10: Number of Products under Development by Universities/Institutes, 2022
Table 11: Products under Development by Companies, 2022
Table 12: Products under Development by Companies, 2022 (Contd..1)
Table 13: Products under Development by Companies, 2022 (Contd..2)
Table 14: Products under Development by Companies, 2022 (Contd..3)
Table 15: Products under Development by Companies, 2022 (Contd..4)
Table 16: Products under Development by Companies, 2022 (Contd..5)
Table 17: Products under Development by Companies, 2022 (Contd..6)
Table 18: Products under Development by Companies, 2022 (Contd..7)
Table 19: Products under Development by Companies, 2022 (Contd..8)
Table 20: Products under Development by Companies, 2022 (Contd..9)
Table 21: Products under Development by Companies, 2022 (Contd..10)
Table 22: Products under Development by Universities/Institutes, 2022
Table 23: Products under Development by Universities/Institutes, 2022 (Contd..1)
Table 24: Number of Products by Stage and Target, 2022<

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings